Galcanezumab-Gnlm
Brand name: Emgality Pen
Rank #180 of 500 drugs by total cost
$87.0M
Total Cost
101,221
Total Claims
$87.0M
Total Cost
3,254
Prescribers
$859
Cost per Claim
7,572
Beneficiaries
115,544
30-Day Fills
$27K
Avg Cost/Provider
31
Avg Claims/Provider
About Galcanezumab-Gnlm
Galcanezumab-Gnlm (sold as Emgality Pen) was prescribed 101,221 times by 3,254 Medicare Part D providers in 2023, costing the program $87.0M. At $859 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 177 | Lamotrigine (Lamotrigine) | $89.0M | 1,603,798 |
| 178 | Insulin Aspart Prot/Insuln Asp (Novolog Mix 70-30 Flexpen) | $88.8M | 79,814 |
| 179 | Teduglutide (Gattex) | $88.4M | 1,758 |
| 180 | Galcanezumab-Gnlm (Emgality Pen) | $87.0M | 101,221 |
| 181 | Imatinib Mesylate (Imatinib Mesylate) | $85.0M | 40,908 |
| 182 | Clopidogrel Bisulfate (Clopidogrel) | $84.7M | 5,428,304 |
| 183 | Famotidine (Famotidine) | $84.3M | 5,257,365 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology